From LG to NSDL: India IPO market gears up for $2.4 billion in offerings in July as confidence rebounds
(You can now subscribe to our
(You can now subscribe to our ETMarkets WhatsApp channel
Indian firms could raise some $2.4 billion through IPOs in July, investment bankers said, raising hopes of a sustained revival in primary offerings after demand was dented by the U.S. trade war and global geopolitical tensions earlier this year.That amount would mark the strongest month since December and would follow a robust $2 billion raised in June, though most of that was raised by one company, HDB Financial Services.Education loan provider Credila Financial Services, National Securities Depository Ltd (NSDL), surveillance firm Aditya Infotech and power-transmission-goods maker M&B Engineering are conducting roadshows and are expected to go public this month, bankers said.They spoke on condition of anonymity as the companies have yet to make the timing of their IPOs and other details public. The companies did not respond to Reuters requests for comment.India's IPO market had its best-ever year in 2024, with $20.5 billion raised, second only to the U.S., riding high on money inflows from domestic investors who have become wealthier on growth in the world's fifth-largest economy and were optimistic about more economic growth.This year was widely expected to be another record year but U.S. President Donald Trump's trade war, tensions with Pakistan and in the Middle East took much wind out of those IPO sails. South Korean conglomerate LG Electronics' India unit and other companies ended up delaying their capital raising plans.Things now look to be getting back on track, particularly with the Nifty 50 and Sensex having regained lost ground to trade about 3% off from their peaks."The IPO market has come back.... The absence of most of the negatives is driving the market more than anything else," said Suraj Krishnaswamy, the managing director of investment banking at Axis Capital So far this year, India continues to the world's No. 2 IPO market with $5.86 billion raised, accounting for the 12% of total proceeds globally, LSEG data shows.The largest offering this month is likely to be Credila, which has said it is seeking $584 million.NSDL, India's largest stock depository, is looking to raise $400 million, according to a banker.NSDL received its regulatory nod for a listing as far back as September but market sentiment trended lower not long after on concerns about slower growth for the economy and corporate profits.Details about the two firms' valuations and IPO dates could be announced soon, bankers said.Other major offerings in the pipeline are LG Electronics India's $1.8 billion IPO, and issues from JSW Cement and defence equipment maker SMPP worth around $470 million each, they added.JSW's offering could come in late July or early August, according to one banker. The timing of the other two was less clear.According to PRIME Database, there are 143 Indian IPOs being planned worth a potential $26 billion. Of those, 73 have been approved by regulators."We expect the upcoming months to be the best for Indian IPO market as compared to what we have seen so far this year," Bhavesh Shah, the managing director and head of investment banking at Equirus.Others, however, were more cautious in their optimism, saying that participation from high net worth individuals and ordinary retail investors is unlikely to be as strong as it was last year."Investors have become far more selective and are now much more mindful about where they see higher potential for returns," said Umesh Agrawal, fund manager at 360 ONE Asset.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
17 minutes ago
- Economic Times
US' new tariff list: India at 25%, exports to get hit, competitors in lower band
Synopsis Effective August 7, 2025, the US has imposed a blanket 25% tariff on all Indian-origin goods, placing India among the most harshly treated nations in its new tariff regime. This measure, part of a new Executive Order, denies India product-level exemptions, even for critical sectors like pharmaceuticals and electronics. Agencies US' new tariff list New Delhi: In a move that could dent India's exports to US, Washington has imposed a blanket 25% tariff on all Indian-origin goods, effective August 7, measure, part of a new Executive Order issued by US President Donald Trump on July 31, places India among the most harshly treated countries in the new American tariff regime, offering no product-level exemptions even for sectors deemed critical like pharmaceuticals, energy, and Order mentions that tariffs may be reduced once countries do a deal with the per the order, countries have been subject to tariffs ranging from 10% to over 41% with differential rates based on geopolitical risk, economic alignment, and trade said the new order puts India at disadvantage to majority competitors including Pakistan, Vietnam, Bangladesh, Turkey where the tariffs are 15-20%. 'India's exports of petroleum products, smartphones, pharmaceuticals, engineering goods, electronics, and textiles will bear the brunt of the tariffs,' said a representative of an export promotion penalty threatened by Trump on India for doing business with Russia has not yet been US, Wednesday, announced 25% tariffs on India along with undisclosed penalty on trading with Russia.'The implications of the recent development are being examined by the government. The Ministry of Commerce and Industry is engaged with all stakeholders including exporters and industry for taking feedback of their assessment of the situation,' commerce and industry minister Piyush Goyal said in his statement in Parliament US was India's largest export destination in FY25 with shipments valued at $86.51 billion. But it accounted for less than a fifth of its total goods exports of $437.42 per the Order, unlike many other trading partners, India has been denied all product-level exemptions—even for products and sectors, the US exempted Goods from other tariff exempted categories include finished pharmaceutical drugs, APIsand other key drug inputs; energy products, critical minerals and a wide range of electronics and EU has been granted a special concession in which if the existing US most favoured nation (MFN) tariff on an EU product is below 15%, the total tariff will be increased to 15%. However, if the MFN tariff is already 15% or higher, then no additional duty will be charged.A 10% tariff applies to a few countries—Brazil, the UK, and the Falkland 15% tariff, which is the most common, covers 38 countries. Countries facing higher tariffs (25-30%) include India, Brunei, Kazakhstan, Moldova, and and Serbia at 35%, Switzerland at 39% (unusually high for a developed nation), Laos and Myanmar at 40%, and Syria at 41%, the US Customs Border Protection authority will realise a guidance clarifying on how this measure will be applied.
Hans India
20 minutes ago
- Hans India
Trump asks 17 non-Indian drug majors to cut prices in US; Nifty pharma dips
Mumbai: A letter from US President Donald Trump has asked 17 global drug giants to cut their prices in the country, sparking severe losses for them, as its impact hit the Indian stock market too. The letter urged that these businesses cut US drug pricing to match prices in other developed markets. Though no Indian pharmaceutical companies received Trump's letters, the Nifty Pharma index reacted sharply, falling 2.45 per cent during the intra-day trade on Friday. The index fell for the third day in a row. Sun Pharmaceutical Industries Ltd fell 3.98 per cent. Aurobindo Pharma lost 3.42 per cent and Granules India lost 3.2 per cent. Gland Pharma, Cipla, and Lupin fell 2 to 3 per cent. The US President wrote to 17 of the world's major pharmaceutical corporations, pressing them to lower drug prices immediately and give assurance that future drugs will be priced in line with other countries. The letters were sent to Eli Lilly, Novo Nordisk, Pfizer, and others, seeking 'Most Favoured Nation' (MFN) pricing for US within 60 days. White House Press Secretary Karoline Leavitt said recent data showed that Americans paid more than three times more for brand-name drugs than other developed nations. Trump had earlier made a similar announcement on May 12, asking pharma companies to cut prices in US. Industry sources in India had then said Trump's proposal might hurt Indian exporters of branded generics to the US, given generic drugs are already sold at low prices. If prices are cut further, it will make shipping unviable, they said. A third of Indian pharmaceutical exports of $30 billion annually, reach the US market. Trump gave drug companies 60 days to voluntarily comply with the new pricing diktat in the letter, failing which, he said, the US would use 'every tool in our arsenal' to protect Americans from 'continued abusive drug pricing' practices. Trump's letter required companies to sell certain drugs directly to patients at prices at which they are offered to third-party insurers.
&w=3840&q=100)
First Post
20 minutes ago
- First Post
Indian imports bill could rise buy $14 billion after stopping Russian oil imports
If India were to stop buying Russian crude oil, Indian imports bill could rise by up to $14 billion as a result of expensive imports from elsewhere. But the true impact on India —and Western nations as well— could be larger as India's purchase of Russian oil has kept international prices low so far. read more Fuga Bluemarine crude oil tanker lies at anchor near the terminal Kozmino in Nakhodka Bay near the port city of Nakhodka, Russia. India's imports bill could rise by up to $14 billion after stopping Russian crude oil imports. In addition to slapping India with 25 per cent tariff, US President Donald Trump has threatened additional penalties over the trade with Russia, mainly the purchase of Russian oil — India has bought discounted Russian oil since Russia launched the war on Ukraine in 2022. The true cost of India replacing Russian oil imports in the wake of Trump's threats would be much higher than $14 billion for India and the world. STORY CONTINUES BELOW THIS AD The true cost of replacing Russian oil for India — and the world India stopping the purchase of Russian oil could raise the price of oil by up to $10 per barrel, raising the country's import bill by around $13-14 billion, according to Prashant Vasisht, the Senior Vice President and Co-Group Head of Corporate Ratings at ICRA. Vasisht suggested the true cost could be higher as prices of gas and other petroleum products and derivatives will also rise. 'Additionally, domestic gas and LNG imports linked to dated Brent prices would also become dearer thereby impacting all gas consumers such as fertiliser, city gas distribution etc. A $10/barrel increase in Brent prices could increase the cost of LNG purchased annually under the RasGas contract by Rs 3,900 crore,' Vasisht told The Financial Express. Between May 2022-2025, India saved around $17.2 billion with the purchase of discounted Russian oil, according to ICRA's calculations. However, that may now change — and not just for India. With the purchase of discounted Russian oil, India and China have so far stabilised oil prices in the international market by absorbing Russian over-supply and easing the pressure on global prices. But, if and when India would stop importing Russian oil, the competition for non-Russian oil would rise and prices will rise as demand will rise in proportion to supply. Western nations will also feel the pinch. Firstly, prices of oil will also rise for them owing to greater demand and limited supply of non-Russian oil. Secondly, since 2022, Indian refiners had been processing Russian crude and selling finished products to Western nations at cheaper rates. As such discounted purchases would end, their bills will rise as well.
